<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887766</url>
  </required_header>
  <id_info>
    <org_study_id>GS-300-001</org_study_id>
    <nct_id>NCT04887766</nct_id>
  </id_info>
  <brief_title>Study on GS300 on NAFLD</brief_title>
  <acronym>REVERT</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of GS300 on Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelesis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gelesis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of GS300 when administered for 24 weeks in patients with&#xD;
      Nonalcoholic Fatty Liver Disease (NAFLD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, placebo-controlled, double-blinded, parallel-group study.&#xD;
      Patients will be randomized 1:1 to receive either GS300 or placebo. The study includes an up&#xD;
      to 6 weeks screening period, a 24-week treatment period, and a 1-week follow-up period.&#xD;
&#xD;
      Approximately 250 patients (125 patients per arm) will be enrolled (at least 40% from each&#xD;
      gender and at least 40% from US and 40% from Europe).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to one of two groups in parallel for the duration of the study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss ≥ 5%</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Proportion of patients with weight loss ≥ 5% at Week 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Placebo-adjusted percent change in weight from Baseline to Week 24</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Placebo-adjusted percent change in weight from Baseline to Week 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative reduction in liver fat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Relative reduction in liver fat from Baseline to Week 24, as measured by hepatic Magnetic Resonance Imaging Proton Density Fat Fraction (MRI PDFF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight loss ≥ 7.5%</measure>
    <time_frame>24 Weeks</time_frame>
    <description>To assess reduction in weight (≥ 7.5%) in patients with NAFLD treated with GS300 or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss ≥ 10%</measure>
    <time_frame>24 Weeks</time_frame>
    <description>To assess reduction in weight (≥ 10%) in patients with NAFLD treated with GS300 or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the percentage of patients with ≥ 30% relative reduction in liver fat</measure>
    <time_frame>24 Weeks</time_frame>
    <description>To evaluate the percentage of patients with ≥ 30% relative reduction in liver fat in patients treated with GS300 or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess placebo-adjusted waist circumference reduction</measure>
    <time_frame>24 Weeks</time_frame>
    <description>To assess placebo-adjusted waist circumference reduction after 24 weeks of treatment with GS300 or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of GS300 on glycemic control in patients with NAFLD</measure>
    <time_frame>24 Weeks</time_frame>
    <description>To assess the impact of GS300 on glycemic control in patients with NAFLD treated with GS300 or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of GS300 on liver enzymes in patients with NAFLD</measure>
    <time_frame>24 Weeks</time_frame>
    <description>To assess the impact of GS300 on liver enzymes in patients with NAFLD treated with GS300 or placebo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intestinal Permeability</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Intestinal permeability - Urine test (sub-population of 50 patients at selected sites).</description>
  </other_outcome>
  <other_outcome>
    <measure>Vitamin Levels</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Serum/plasma vitamin levels (sub-population at selected sites).</description>
  </other_outcome>
  <other_outcome>
    <measure>Gut Peptides</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Glucagon-like Peptide-1 (GLP-1), Glucagon-like Peptide-2 (GLP-2), Gastric Inhibitory Polypeptide (GIP), ghrelin, somatostatin, Cholecystokinin (CCK), Peptide YY (PYY).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Nonalcoholic Fatty Liver</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GS300: Three (3) GS300 capsules [approximately 0.65 grams (g)] two (2) times per day ingested 10 minutes (min) before meals (i.e., lunch and dinner) - total of 3.9 g per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Three (3) placebo capsules two (2) times per day 10 min before meals (i.e., lunch and dinner)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GS300</intervention_name>
    <description>Gelesis300 hydrogel in gelatin capsules</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 22 years and ≤ 65 years&#xD;
&#xD;
          2. Body Mass Index (BMI) ≥ 27 and ≤ 40 kilogram (kg)/meter2 (m2)&#xD;
&#xD;
          3. Negative for Hepatitis B, C and Human Immunodeficiency Virus (HIV) within 6 months of&#xD;
             screening [HbsAg negative and Hepatitis C Virus (HCV) RNA negative; subjects treated&#xD;
             and cured of HCV must have completed treatment and tested negative for HCV at least 2&#xD;
             years prior to study enrollment]&#xD;
&#xD;
          4. Fibroscan CAP score &gt; 300 decibels (dB)/m&#xD;
&#xD;
          5. Stable body weight defined as less than 5% change in body weight in the 3 months prior&#xD;
             to screening (per patient report)&#xD;
&#xD;
          6. Approximately 250 patients (approximately 125 patients per treatment arm)&#xD;
&#xD;
               1. Prediabetes i) Untreated prediabetic patients with FPG ≥ 100 mg/ dL (≥ 5.6&#xD;
                  mmol/L) and &lt; 126 mg/dL (&lt; 7.0 mmol/L) at both Screening Visits with HbA1c ≤ 6.4%&#xD;
                  (≤ 46 mmol/mol) - if only one value is within this range, the other value should&#xD;
                  not be ≥ 126 mg/dL (≥ 7.0 mmol/L) and HbA1c should be ≥ 5.7% (≥ 39 mmol/mol) and&#xD;
                  ≤ 6.4% (≤ 46 mmol/mol) ii) Drug-treated (metformin) prediabetic patients with FPG&#xD;
                  ≥ 70 mg/dL (≥ 3.9 mmol/L) and &lt; 126 mg/dL (&lt; 7.0 mmol/L) at both Screening Visits&#xD;
&#xD;
               2. Type 2 Diabetes i) Untreated type 2 diabetic patients with FPG ≤ 200 mg/dL (≤&#xD;
                  11.2 mmol/L) at both Screening Visits and either FPG ≥ 126 mg/dL (≥ 7.0 mmol/L)&#xD;
                  at both Screening Visits or FPG &lt; 126 mg/dL (&lt; 7.0 mmol/L) at one or both&#xD;
                  Screening Visits with HbA1c ≥ 6.5% (≥ 48 mmol/mol) ii) Drug-treated [metformin&#xD;
                  and/or dipeptidyl peptidase-4 (DPP-4) inhibitors, and/or insulin] type 2 diabetic&#xD;
                  patients with FPG ≥ 70 mg/dL (≥ 3.9 mmol/L) and ≤ 270 mg/dL (≤ 15.1 mmol/L) at&#xD;
                  both Screening Visits Note, approximately 10% to 20% of enrolled Type 2 diabetic&#xD;
                  patients will be on insulin therapy&#xD;
&#xD;
               3. Normoglycemia (up to approximately 10% of patients) Normoglycemic patients with&#xD;
                  FPG ≥ 70 mg/dL (≥ 3.9 mmol/L) and &lt; 100 mg/ dL (&lt; 5.6 mmol/L) at both Screening&#xD;
                  Visits with HbA1c &lt; 5.7% (&lt; 39 mmol/mol) and HOMA-IR ≥ 3.0&#xD;
&#xD;
          7. MRI PDFF ≥ 10%&#xD;
&#xD;
          8. Willing to sign the ICF prior to any study related procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Self-reported alcohol intake &gt; 20 gram (g)/day for women and &gt; 30 g/day for men (on&#xD;
             average per day) as per medical history&#xD;
&#xD;
          2. Alcohol Use Disorders Identification Test (AUDIT) questionnaire: AUDIT-C score of ≥ 4&#xD;
             in men and ≥ 3 in women will be followed by a full AUDIT questionnaire by interview&#xD;
             with patients excluded for score ≥ 8&#xD;
&#xD;
          3. Prior liver transplant&#xD;
&#xD;
          4. Liver cirrhosis as evidenced by any of the following:&#xD;
&#xD;
               -  Serum albumin &lt; 3.5 g/dL (0.53 mmol/L)&#xD;
&#xD;
               -  INR &gt; 1.3 (unless due to anticoagulant therapy)&#xD;
&#xD;
               -  AST/ALT ratio ≥ 2&#xD;
&#xD;
               -  Direct bilirubin &gt; 0.3 mg/dL (5.13 micromol (micromol)/L)&#xD;
&#xD;
               -  Platelet count &lt; 150,000/microL&#xD;
&#xD;
          5. History or evidence of other chronic liver diseases, including, but not limited to the&#xD;
             following:&#xD;
&#xD;
               -  Current active autoimmune hepatitis&#xD;
&#xD;
               -  Primary biliary cholangitis (PBC)&#xD;
&#xD;
               -  Primary sclerosing cholangitis&#xD;
&#xD;
               -  Wilson's disease&#xD;
&#xD;
               -  Alpha-1-antitrypsin (A1AT) deficiency&#xD;
&#xD;
               -  Hemochromatosis&#xD;
&#xD;
               -  Drug-induced liver disease, as defined on the basis of typical exposure and&#xD;
                  history&#xD;
&#xD;
               -  Bile duct obstruction&#xD;
&#xD;
               -  Suspected or proven liver cancer&#xD;
&#xD;
               -  History of hepatic encephalopathy&#xD;
&#xD;
               -  Portal hypertension (esophageal varices, ascites, splenomegaly)&#xD;
&#xD;
          6. History of gastric surgery (up to 10% patients with history of gastric bypass or&#xD;
             sleeve gastrectomy may be enrolled if the surgery occurred more than 6 months prior to&#xD;
             enrollment and patients had a weight change &lt; 5% during the 3 months prior to&#xD;
             enrollment)&#xD;
&#xD;
          7. Angina, coronary bypass, or myocardial infarction within 6 months prior to Screening&#xD;
             Visit&#xD;
&#xD;
          8. Inflammatory bowel disease, celiac disease, or other significant gastrointestinal&#xD;
             disease - for example, a history of bowel obstruction without surgical correction&#xD;
             (patients with irritable bowel syndrome may be enrolled)&#xD;
&#xD;
          9. Pregnancy&#xD;
&#xD;
         10. Absence of medically approved contraceptive methods in females of childbearing&#xD;
             potential (e.g., hysterectomy, oral contraceptives, non-oral contraceptive medications&#xD;
             or intrauterine device combined with a barrier method, two combined barrier methods&#xD;
             such as diaphragm and condom or spermicide, or condom and spermicide; bilateral tubal&#xD;
             ligation and vasectomy are not acceptable methods)&#xD;
&#xD;
         11. Type 1 Diabetes&#xD;
&#xD;
         12. HbA1c &gt; 8.5% (&gt; 69 mmol/mol)&#xD;
&#xD;
         13. Serum LDL-C ≥ 160 mg/dL (≥ 4.15 mmol/L)&#xD;
&#xD;
         14. Serum triglycerides ≥ 350 mg/dL (≥ 3.96 mmol/L)&#xD;
&#xD;
         15. Use of any medications for the treatment of diabetes within 3 months prior to&#xD;
             enrollment. Note, metformin, DPP-4 inhibitors, and insulin at a stable dose over the&#xD;
             last 3 months are allowed. Insulin dose variance of 20% (decrease or increase) is&#xD;
             allowed.&#xD;
&#xD;
         16. Any change in standard of care or background therapy for liver disease or other&#xD;
             ongoing chronic conditions within 3 months prior to enrollment, including changes in&#xD;
             the following:&#xD;
&#xD;
               -  Antidiabetic medications (metformin, DPP-4 inhibitors, insulin)&#xD;
&#xD;
               -  Thyroid hormones&#xD;
&#xD;
               -  Medications treating depression&#xD;
&#xD;
               -  Medications treating dyslipidemia&#xD;
&#xD;
               -  Medications treating hypertension&#xD;
&#xD;
               -  Vitamin E&#xD;
&#xD;
         17. Regular/daily use of any of the following within 3 months prior to enrollment or&#xD;
             anticipated regular/daily use during the study period:&#xD;
&#xD;
               -  High dose nonsteroidal anti-inflammatory drugs (NSAIDS) (equivalent of &gt; 3,200&#xD;
                  mg/day ibuprofen)&#xD;
&#xD;
               -  Systemic corticosteroids, anabolic steroids&#xD;
&#xD;
               -  Methotrexate, amiodarone, tamoxifen, tetracyclines, estrogens at doses greater&#xD;
                  than those used for hormone replacement, valproic acid&#xD;
&#xD;
               -  Probiotic supplements (yogurt is allowed)&#xD;
&#xD;
               -  Addictive, non-prescribed medications including amphetamines, barbiturates,&#xD;
                  cocaine, opiates, methadone and phencyclidine as per medical history or regular&#xD;
                  daily use of cannabinoids&#xD;
&#xD;
         18. Use of any anti-obesity medications (including herbal preparations) within 2 months&#xD;
             prior to enrollment or any anticipated use during the study period&#xD;
&#xD;
         19. History of allergic reaction to carboxymethylcellulose (CMC), citric acid, sodium&#xD;
             stearyl fumarate, raw cane sugar, gelatin, or titanium dioxide&#xD;
&#xD;
         20. Currently enrolled in another investigational device or drug study, or less than 3&#xD;
             months since ending another investigational device or drug study(s), or receiving&#xD;
             other investigational treatment(s)&#xD;
&#xD;
         21. Any disease or condition that, in the opinion of the investigator or Sponsor, would&#xD;
             interfere with study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan M Heshmati, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gelesis, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Manager</last_name>
    <phone>1-857-299-7261</phone>
    <email>kmartin@gelesis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dir Clinical Operations</last_name>
    <phone>1-857-201-5330</phone>
    <email>hcalderon@gelesis.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

